To The Moon

Hi Tigers!💰Check the hottest stocks in the past 24 hours on our Tiger Trade app and other websites, to find a potential stock to buy! 💰Welcome to read through this article and join our topic to win coins!1. The Most Searched Stocks in the Tiger Trade App$Tesla Motors(TSLA)$ $NVIDIA Corp(NVDA)$ $Palantir Technologies Inc.(PLTR)$ $Apple(AAPL)$

Everyone is waiting impatiently for $Apple(AAPL)$’s Q2 2023 quarterly earnings that will be released later today - Thu, 04 May 2023. It is the last FAANG member to release its results. Before hearing the actuals, below please find Wall Street’s expectations (gathered from 24 analysts). Revenue. Between $89.79 Billion (low) and $98.84 Billion (high). Average - $92.94 Billion. EPS. Between low & high estimates of $1.37 & $1.56. Average - $1.43. These estimates would be slightly below its Q2 2022 record-breaking revenue of $97.3 Billion & EPS of $1.54. Overall, many expect APPLE Inc to report a strong Q2 2023 performance. Of the numerous revenue streams, below are two possible bright sparks that would be holding Apple’s earnings fort. (1)

At 2:00 pm Eastern Time on May 3, the Fed raised interest rates by 25 basis points to 5.00%-5.25% as scheduled, in line with expectations, announcing that this round of interest rate hike cycle is basically over.Every time the market uses the official announcement of the Fed to try to figure out the connotation of Powell's reply in the question session. The question on the 3rd is very transparent. The following are the main points of his reply:1) Future interest rate policy towards a "data dependent" approach;2) This meeting did not make a clear decision on whether to stop raising interest rates;3) More data is needed to see whether the Fed funds rate is sufficiently restrictive;4) More rate hikes are still possible if greater monetary policy constraints are required;5) It is too early to

Pharmaceutical giant Pfizer Inc. reported its first quarter 2023 results before the market on Tuesday, May 2, reporting revenue of $18.28 billion for the quarter, still beating previous estimates, despite a sharp decline in revenue related to new crowns. I. Company Profile Pfizer is an international pharmaceutical giant dedicated to the development of healthcare products, with specific businesses in pharmaceuticals, vaccines and consumer health. Second, financial analysis: the period of epidemic windfall passed, revenue and net profit dropped sharply, but better than expected On the revenue side, Pfizer's revenue for the first quarter was $18.28 billion, down 28.8% year-over-year, exceeding previous estimates of $16.6 billion. Pfizer's current revenue composition can be divided into three